| 000 | 01777 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516175028.0 | ||
| 264 | 0 | _c20140708 | |
| 008 | 201407s 0 0 eng d | ||
| 022 | _a1465-993X | ||
| 024 | 7 |
_a10.1186/1465-9921-14-113 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBaarsma, Hoeke A | |
| 245 | 0 | 0 |
_aPharmacological inhibition of GSK-3 in a guinea pig model of LPS-induced pulmonary inflammation: I. Effects on lung remodeling and pathology. _h[electronic resource] |
| 260 |
_bRespiratory research _cOct 2013 |
||
| 300 |
_a113 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCollagen _xmetabolism |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aFibronectins _xmetabolism |
| 650 | 0 | 4 |
_aGlycogen Synthase Kinase 3 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aGuinea Pigs |
| 650 | 0 | 4 |
_aIndoles _xpharmacology |
| 650 | 0 | 4 |
_aLipopolysaccharides _xadverse effects |
| 650 | 0 | 4 |
_aLung _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMaleimides _xpharmacology |
| 650 | 0 | 4 |
_aMuscle, Smooth _xdrug effects |
| 650 | 0 | 4 |
_aPulmonary Disease, Chronic Obstructive _xchemically induced |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aSmad Proteins _xmetabolism |
| 650 | 0 | 4 |
_abeta Catenin _xmetabolism |
| 700 | 1 | _aBos, Sophie | |
| 700 | 1 | _aMeurs, Herman | |
| 700 | 1 | _aVisser, Kim H | |
| 700 | 1 | _aSmit, Marieke | |
| 700 | 1 | _aSchols, Annemie M W J | |
| 700 | 1 | _aLangen, Ramon C | |
| 700 | 1 | _aKerstjens, Huib A M | |
| 700 | 1 | _aGosens, Reinoud | |
| 773 | 0 |
_tRespiratory research _gvol. 14 _gp. 113 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1465-9921-14-113 _zAvailable from publisher's website |
| 999 |
_c23195887 _d23195887 |
||